Dropping The 52 Week Low, Teligent Inc (Nasdaq:TLGT) Ending The Day At $1.86

0
11
Car Wreck freeimages.com/dimitri_c
Car Wreck freeimages.com/dimitri_c

Teligent Inc (Nasdaq:TLGT)

December 5th, 2018
Amidst falling markets Teligent Inc fell $0.13 Tuesday, down 6.53%, closing at $1.86. As well as the drop in value, Teligent Inc hit a new 52 week low of $1.85, breaking the previous low of $1.95 from earlier this month. Two technical ‘scores’ for companies to be aware of are the Altman Z1 and the Piotroski2 scores. TLGT scored rather low for both, which could be indicators of trouble down the road (the Altman Z-Score is -0.29, and the Piotroski Score is 1).

TLGT was outperformed by the rest of the Healthcare sector which went down only 2.30%.

Market Sectors

The market sectors were mixed Wednesday with a majority of the sectors trending down. Utilities saw the biggest increase of the day (0.15%), while Financials saw the biggest drop (4.40%). Healthcare has seen the biggest year-to-date gain at 13%. The biggest loss this year has been the Communication Services sector declining 13%.

Utilities saw the biggest turnaround from its 5-day performance of 2.31%, as it went up 0.15%. Industrials and Consumer Discretionary saw turn arounds from their five day positive performance, Industrials with a drop of 4.35%.

Sector Breakdown

  • Utilities went up with a 0.15% change.
  • Real Estate went down with a -1.26% change.
  • Consumer Staples went down with a -1.63% change.
  • Healthcare went down with a -2.30% change.
  • Energy went down with a -2.93% change.
  • Materials went down with a -3.08% change.
  • Communication Services went down with a -3.14% change.
  • Information Technology went down with a -3.86% change.
  • Consumer Discretionary went down with a -3.91% change.
  • Industrials went down with a -4.35% change.
  • Financials went down with a -4.40% change.

Teligent Inc Info

Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company’s products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract manufacturing and formulation services. Teligent, Inc. sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Teligent Inc’s score is -0.29) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Teligent Inc’s score is 1), and 9 is the best.

TLGT daily update

TLGT daily update
TLGT daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.